{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:53:42Z","timestamp":1791496422384,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021790","name":"Fondation pour la Recherche sur Alzheimer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Next Generation EU [DM 1557 11.10.2022]"],"award-info":[{"award-number":["Next Generation EU [DM 1557 11.10.2022]"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00415-024-12221-7","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T10:02:17Z","timestamp":1708509737000},"page":"2716-2729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5804-3378","authenticated-orcid":false,"given":"Elisa","family":"Canu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2063-7735","authenticated-orcid":false,"given":"Giulia","family":"Rugarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7717-6406","authenticated-orcid":false,"given":"Federico","family":"Coraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-6243","authenticated-orcid":false,"given":"Silvia","family":"Basaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6544-410X","authenticated-orcid":false,"given":"Giordano","family":"Cecchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Francesca","family":"Calloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3568-4946","authenticated-orcid":false,"given":"Paolo Quintiliano","family":"Vezzulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-7221","authenticated-orcid":false,"given":"Edoardo Gioele","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-2703","authenticated-orcid":false,"given":"Roberto","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3072-1218","authenticated-orcid":false,"given":"Francesca","family":"Caso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-8755","authenticated-orcid":false,"given":"Andrea","family":"Falini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8436-2903","authenticated-orcid":false,"given":"Giuseppe","family":"Magnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-0479","authenticated-orcid":false,"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-4979","authenticated-orcid":false,"given":"Federica","family":"Agosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"12221_CR1","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, Cummings J, van der Flier WM (2021) Alzheimer\u2019s disease. Lancet 397:1577\u20131590","journal-title":"Lancet"},{"key":"12221_CR2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson O (2021) Biomarkers for neurodegenerative diseases. Nat Med 27:954\u2013963","journal-title":"Nat Med"},{"key":"12221_CR3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"12221_CR4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R, Contributors (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562","journal-title":"Alzheimers Dement"},{"key":"12221_CR5","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","volume":"17","author":"H Hampel","year":"2021","unstructured":"Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo A (2021) Developing the ATX(N) classification for use across the Alzheimer disease continuum. Nat Rev Neurol 17:580\u2013589","journal-title":"Nat Rev Neurol"},{"key":"12221_CR6","doi-asserted-by":"crossref","first-page":"e1635","DOI":"10.1212\/WNL.0000000000008361","volume":"93","author":"D Altomare","year":"2019","unstructured":"Altomare D, de Wilde A, Ossenkoppele R, Pelkmans W, Bouwman F, Groot C, van Maurik I, Zwan M, Yaqub M, Barkhof F, van Berckel BN, Teunissen CE, Frisoni GB, Scheltens P, van der Flier WM (2019) Applying the ATN scheme in a memory clinic population: the ABIDE project. Neurology 93:e1635\u2013e1646","journal-title":"Neurology"},{"key":"12221_CR7","first-page":"248","volume":"6","author":"SC Burnham","year":"2019","unstructured":"Burnham SC, Coloma PM, Li QX, Collins S, Savage G, Laws S, Doecke J, Maruff P, Martins RN, Ames D, Rowe CC, Masters CL, Villemagne VL (2019) Application of the NIA-AA research framework: towards a biological definition of Alzheimer\u2019s disease using cerebrospinal fluid biomarkers in the AIBL study. J Prev Alzheimers Dis 6:248\u2013255","journal-title":"J Prev Alzheimers Dis"},{"key":"12221_CR8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00259-019-04536-9","volume":"47","author":"A Dodich","year":"2020","unstructured":"Dodich A, Mendes A, Assal F, Chicherio C, Rakotomiaramanana B, Andryszak P, Festari C, Ribaldi F, Scheffler M, Schibli R, Schwarz AJ, Zekry D, Lovblad KO, Boccardi M, Unschuld PG, Gold G, Frisoni GB, Garibotto V (2020) The A\/T\/N model applied through imaging biomarkers in a memory clinic. Eur J Nucl Med Mol Imaging 47:247\u2013255","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12221_CR9","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.2019.7437","volume":"321","author":"CR Jack Jr","year":"2019","unstructured":"Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, Lowe VJ, Vemuri P, Machulda MM, Schwarz CG, Gunter JL, Senjem ML, Graff-Radford J, Jones DT, Roberts RO, Rocca WA, Petersen RC (2019) Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321:2316\u20132325","journal-title":"JAMA"},{"key":"12221_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neurobiolaging.2023.03.007","volume":"127","author":"K Kasuga","year":"2023","unstructured":"Kasuga K, Tsukie T, Kikuchi M, Tokutake T, Washiyama K, Shimizu S, Yoshizawa H, Kuroha Y, Yajima R, Mori H, Arakawa Y, Onda K, Miyashita A, Onodera O, Iwatsubo T, Ikeuchi T, Japanese Alzheimer\u2019s Disease Neuroimaging I (2023) The clinical application of optimized AT(N) classification in Alzheimer\u2019s clinical syndrome (ACS) and non-ACS conditions. Neurobiol Aging 127:23\u201332","journal-title":"Neurobiol Aging"},{"key":"12221_CR11","volume":"15","author":"TA Pascoal","year":"2023","unstructured":"Pascoal TA, Leuzy A, Therriault J, Chamoun M, Lussier F, Tissot C, Strandberg O, Palmqvist S, Stomrud E, Ferreira PCL, Ferrari-Souza JP, Smith R, Benedet AL, Gauthier S, Hansson O, Rosa-Neto P (2023) Discriminative accuracy of the A\/T\/N scheme to identify cognitive impairment due to Alzheimer\u2019s disease. Alzheimers Dement (Amst) 15:e12390","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"12221_CR12","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00259-023-06311-3","volume":"50","author":"DE Peretti","year":"2023","unstructured":"Peretti DE, Ribaldi F, Scheffler M, Chicherio C, Frisoni GB, Garibotto V (2023) Prognostic value of imaging-based ATN profiles in a memory clinic cohort. Eur J Nucl Med Mol Imaging 50(11):3313\u20133323","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12221_CR13","first-page":"381","volume":"10","author":"J Therriault","year":"2023","unstructured":"Therriault J, Gauthier S, Rosa-Neto P (2023) Adding the topographical information from Tau-PET to the A\/T\/(N) framework: steps towards staging AD in vivo. J Prev Alzheimers Dis 10:381\u2013386","journal-title":"J Prev Alzheimers Dis"},{"issue":"10","key":"12221_CR14","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1002\/alz.13413","volume":"19","author":"ZB Wang","year":"2023","unstructured":"Wang ZB, Tan L, Gao PY, Ma YH, Fu Y, Sun Y, Yu JT, Alzheimer\u2019s Disease Neuroimaging I (2023) Associations of the A\/T\/N profiles in PET, CSF, and plasma biomarkers with Alzheimer\u2019s disease neuropathology at autopsy. Alzheimers Dement 19(10):4421\u20134435","journal-title":"Alzheimers Dement"},{"issue":"9","key":"12221_CR15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jamaneurol.2023.2338","volume":"80","author":"P Erickson","year":"2023","unstructured":"Erickson P, Simren J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, Langhough R, Jonaitis EM, Van Hulle CA, Betthauser TJ, Carlsson CM, Asthana S, Ashton NJ, Johnson SC, Shaw LM, Blennow K, Andreasson U, Bendlin BB, Zetterberg H, Cohort A (2023) Prevalence and clinical implications of a beta-amyloid-negative, tau-positive cerebrospinal fluid biomarker profile in Alzheimer disease. JAMA Neurol 80(9):969\u2013979","journal-title":"JAMA Neurol"},{"key":"12221_CR16","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/WNL.0000000000009724","volume":"95","author":"JL Ebenau","year":"2020","unstructured":"Ebenau JL, Timmers T, Wesselman LMP, Verberk IMW, Verfaillie SCJ, Slot RER, van Harten AC, Teunissen CE, Barkhof F, van den Bosch KA, van Leeuwenstijn M, Tomassen J, Braber AD, Visser PJ, Prins ND, Sikkes SAM, Scheltens P, van Berckel BNM, van der Flier WM (2020) ATN classification and clinical progression in subjective cognitive decline: the SCIENCe project. Neurology 95:e46\u2013e58","journal-title":"Neurology"},{"key":"12221_CR17","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1093\/brain\/awac297","volume":"145","author":"TJ Oberstein","year":"2022","unstructured":"Oberstein TJ, Schmidt MA, Florvaag A, Haas AL, Siegmann EM, Olm P, Utz J, Spitzer P, Doerfler A, Lewczuk P, Kornhuber J, Maler JM (2022) Amyloid-beta levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. Brain 145:4032\u20134041","journal-title":"Brain"},{"key":"12221_CR18","first-page":"197","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, Dent G, Hansson O, Harrison K, von Hehn C, Iwatsubo T, Mallinckrodt C, Mummery CJ, Muralidharan KK, Nestorov I, Nisenbaum L, Rajagovindan R, Skordos L, Tian Y, van Dyck CH, Vellas B, Wu S, Zhu Y, Sandrock A (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9:197\u2013210","journal-title":"J Prev Alzheimers Dis"},{"issue":"6","key":"12221_CR19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM, Investigators T-A (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"key":"12221_CR20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321","journal-title":"N Engl J Med"},{"key":"12221_CR21","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/jgs.17530","volume":"70","author":"A Padovani","year":"2022","unstructured":"Padovani A, Caratozzolo S, Rozzini L, Pilotto A, Benussi A, Tedeschi G (2022) \u201cReal-world\u201d eligibility for aducanumab depends on clinical setting and patients\u2019 journey. J Am Geriatr Soc 70:626\u2013628","journal-title":"J Am Geriatr Soc"},{"key":"12221_CR22","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1111\/jgs.17390","volume":"69","author":"M Canevelli","year":"2021","unstructured":"Canevelli M, Rossi PD, Astrone P, Consorti E, Vanacore N, Cesari M (2021) \u201cReal world\u201d eligibility for aducanumab. J Am Geriatr Soc 69:2995\u20132998","journal-title":"J Am Geriatr Soc"},{"key":"12221_CR23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-029663","volume":"9","author":"S Epelbaum","year":"2019","unstructured":"Epelbaum S, Paquet C, Hugon J, Dumurgier J, Wallon D, Hannequin D, Jonveaux T, Besozzi A, Pouponneau S, Hommet C, Blanc F, Berly L, Julian A, Paccalin M, Pasquier F, Bellet J, Boutoleau-Bretonniere C, Charriau T, Rouaud O, Madec O, Mouton A, David R, Bekadar S, Fabre R, Liegey E, Deberdt W, Robert P, Dubois B (2019) How many patients are eligible for disease-modifying treatment in Alzheimer\u2019s disease? A French national observational study over 5 years. BMJ Open 9:e029663","journal-title":"BMJ Open"},{"key":"12221_CR24","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2022) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association Publishin, Washington, DC, US","DOI":"10.1176\/appi.books.9780890425787"},{"key":"12221_CR25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000117270","volume":"36","author":"F Pasquier","year":"1996","unstructured":"Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 36:268\u2013272","journal-title":"Eur Neurol"},{"key":"12221_CR26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol 149:351\u2013356","journal-title":"AJR Am J Roentgenol"},{"key":"12221_CR27","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archneur.63.11.1627","volume":"63","author":"RR Davies","year":"2006","unstructured":"Davies RR, Kipps CM, Mitchell J, Kril JJ, Halliday GM, Hodges JR (2006) Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol 63:1627\u20131631","journal-title":"Arch Neurol"},{"key":"12221_CR28","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/jnnp.55.10.967","volume":"55","author":"P Scheltens","year":"1992","unstructured":"Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J (1992) Atrophy of medial temporal lobes on MRI in \u201cprobable\u201d Alzheimer\u2019s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 55:967\u2013972","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12221_CR29","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s00330-011-2205-4","volume":"21","author":"EL Koedam","year":"2011","unstructured":"Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP (2011) Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21:2618\u20132625","journal-title":"Eur Radiol"},{"key":"12221_CR30","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1007\/s00259-020-05175-1","volume":"48","author":"SP Caminiti","year":"2021","unstructured":"Caminiti SP, Sala A, Presotto L, Chincarini A, Sestini S, Perani D, Alzheimer\u2019s Disease Neuroimaging Initiative ftAIMNdTANS-Gc, Schillaci O, Berti V, Calcagni ML, Cistaro A, Morbelli S, Nobili F, Pappata S, Volterrani D, Gobbo CL (2021) Validation of FDG-PET datasets of normal controls for the extraction of SPM-based brain metabolism maps. Eur J Nucl Med Mol Imaging 48:2486\u20132499","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"12221_CR31","first-page":"362","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10:362\u2013377","journal-title":"J Prev Alzheimers Dis"},{"key":"12221_CR32","first-page":"221","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, Sabbagh M, Selkoe D, Weiner M, Salloway S (2022) Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis 9:221\u2013230","journal-title":"J Prev Alzheimers Dis"},{"key":"12221_CR33","doi-asserted-by":"crossref","first-page":"e2102","DOI":"10.1212\/WNL.0000000000201043","volume":"99","author":"A Rosenberg","year":"2022","unstructured":"Rosenberg A, Ohlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Ryden M, Thunborg C, Wiggenraad F, Sandebring-Matton A, Solomon A, Kivipelto M (2022) beta-Amyloid, Tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population. Neurology 99:e2102\u2013e2113","journal-title":"Neurology"},{"key":"12221_CR34","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1212\/WNL.0000000000007821","volume":"93","author":"AC van Loenhoud","year":"2019","unstructured":"van Loenhoud AC, van der Flier WM, Wink AM, Dicks E, Groot C, Twisk J, Barkhof F, Scheltens P, Ossenkoppele R, Alzheimer\u2019s Disease Neuroimaging I (2019) Cognitive reserve and clinical progression in Alzheimer disease: a paradoxical relationship. Neurology 93:e334\u2013e346","journal-title":"Neurology"},{"key":"12221_CR35","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006171","volume":"2","author":"S Weintraub","year":"2012","unstructured":"Weintraub S, Wicklund AH, Salmon DP (2012) The neuropsychological profile of Alzheimer disease. Cold Spring Harb Perspect Med 2:a006171","journal-title":"Cold Spring Harb Perspect Med"},{"key":"12221_CR36","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s11596-020-2282-1","volume":"40","author":"JL Gu","year":"2020","unstructured":"Gu JL, Liu F (2020) Tau in Alzheimer\u2019s disease: pathological alterations and an attractive therapeutic target. Curr Med Sci 40:1009\u20131021","journal-title":"Curr Med Sci"},{"key":"12221_CR37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239\u2013259","journal-title":"Acta Neuropathol"},{"key":"12221_CR38","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab158","volume":"3","author":"M Bocchetta","year":"2021","unstructured":"Bocchetta M, Malpetti M, Todd EG, Rowe JB, Rohrer JD (2021) Looking beneath the surface: the importance of subcortical structures in frontotemporal dementia. Brain Commun 3:fcab158","journal-title":"Brain Commun"},{"key":"12221_CR39","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1007\/s00415-022-11095-x","volume":"269","author":"S Heikkinen","year":"2022","unstructured":"Heikkinen S, Cajanus A, Katisko K, Hartikainen P, Vanninen R, Haapasalo A, Kruger J, Remes AM, Solje E (2022) Brainstem atrophy is linked to extrapyramidal symptoms in frontotemporal dementia. J Neurol 269:4488\u20134497","journal-title":"J Neurol"},{"key":"12221_CR40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12883-021-02325-2","volume":"21","author":"A Molinder","year":"2021","unstructured":"Molinder A, Ziegelitz D, Maier SE, Eckerstrom C (2021) Validity and reliability of the medial temporal lobe atrophy scale in a memory clinic population. BMC Neurol 21:289","journal-title":"BMC Neurol"},{"key":"12221_CR41","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1007\/s00330-021-08340-8","volume":"31","author":"A Rau","year":"2021","unstructured":"Rau A, Urbach H (2021) The MTA score-simple and reliable, the best for now? Eur Radiol 31:9057\u20139059","journal-title":"Eur Radiol"},{"key":"12221_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5789","author":"Z Togher","year":"2022","unstructured":"Togher Z, Dolphin H, Russell C, Ryan M, Kennelly SP, O\u2019Dowd S (2022) Potential eligibility for Aducanumab therapy in an Irish specialist cognitive service-Utilising cerebrospinal fluid biomarkers and appropriate use criteria. Int J Geriatr Psychiatry. https:\/\/doi.org\/10.1002\/gps.5789","journal-title":"Int J Geriatr Psychiatry"},{"key":"12221_CR43","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770","author":"RR Pittock","year":"2023","unstructured":"Pittock RR, Aakre J, Castillo AM, Ramanan VK, Kremers WK, Jack CR, Vemuri P, Lowe VJ, Knopman DS, Petersen RC, Graff-Radford J, Vassilaki M (2023) Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000207770","journal-title":"Neurology"},{"key":"12221_CR44","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114408","volume":"14","author":"A Leuzy","year":"2022","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O (2022) Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med 14:e14408","journal-title":"EMBO Mol Med"},{"key":"12221_CR45","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.neurobiolaging.2010.05.020","volume":"33","author":"JD Rohrer","year":"2012","unstructured":"Rohrer JD, Rossor MN, Warren JD (2012) Alzheimer\u2019s pathology in primary progressive aphasia. Neurobiol Aging 33:744\u2013752","journal-title":"Neurobiol Aging"},{"key":"12221_CR46","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/brain\/awm213","volume":"130","author":"S Alladi","year":"2007","unstructured":"Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR (2007) Focal cortical presentations of Alzheimer\u2019s disease. Brain 130:2636\u20132645","journal-title":"Brain"},{"key":"12221_CR47","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/jnnp.2010.221853","volume":"82","author":"B Borroni","year":"2011","unstructured":"Borroni B, Premi E, Agosti C, Alberici A, Cerini C, Archetti S, Lanari A, Paghera B, Lucchini S, Caimi L, Padovani A (2011) CSF Alzheimer\u2019s disease-like pattern in corticobasal syndrome: evidence for a distinct disorder. J Neurol Neurosurg Psychiatry 82:834\u2013838","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12221-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12221-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12221-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T02:22:01Z","timestamp":1731378121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12221-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["12221"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12221-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"6 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"E. Canu receives research supports from the Italian Ministry of Health; G. Rugarli and F. Coraglia have nothing to disclose; S. Basaia receives research support from the Italian Ministry of Health; G. Cecchetti has received speaker honoraria from Neopharmed Gentili; S.F. Calloni, P.Q. Vezzulli, R. Santangelo, E.G. Spinelli, F. Caso, A. Falini, G. Magnani have nothing to disclose; M. Filippi is Editor-in-Chief of the <i>Journal of Neurology<\/i>, Associate Editor of <i>Human Brain Mapping<\/i>, <i>Neurological Sciences,<\/i> and <i>Radiology<\/i>, received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi, speaking activities from Bayer, Biogen, Celgene, Chiesi Italia Spa, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA, participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda, scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme, he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla; F. Agosta is Associate Editor of NeuroImage: Clinical, has received speaker honoraria from Biogen Idec, Italfarmaco, Roche, Zambon and Eli Lilly, and receives or has received research supports from the Italian Ministry of Health, the Italian Ministry of University and Research, AriSLA (Fondazione Italiana di Ricerca per la SLA), the European Research Council, the EU Joint Programme \u2013 Neurodegenerative Disease Research (JPND), and Foundation Research on Alzheimer Disease (France).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The ethical standards committee on human experimentation of IRCCS San Raffaele Scientific Institute (Milan, Italy) approved the study protocol and all participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}